Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 65, Issue 11, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01424-21
Keywords
Acinetobacter; cefiderocol; durlobactam; sulbactam
Categories
Funding
- NIH/NIAID
Ask authors/readers for more resources
This study reports the successful treatment of carbapenem-resistant Acinetobacter baumannii infections using a novel combination therapy, showing promising results in in vitro experiments but requiring further evaluation of its clinical efficacy.
Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are challenging to treat and associated with poor clinical outcomes. In this issue, sulbactam-durlobactam, a novel beta-lactam-beta-lactamase inhibitor, was used with cefiderocol to successfully treat CRAB pneumonia. While this report and in vitro data are encouraging, determining the impact of treatment regimens on clinical outcomes after CRAB infections is not straightforward. Therefore, careful evaluation in pathogen-directed randomized controlled trials is needed to determine the optimal treatment of CRAB infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available